ALSO NOTED: Coley touts Phase I data; Covance expands to China, Singapore; and much more...

> The FDA has cleared AstraZeneca to start marketing Nexium to kids 12 to 17 with GERD. Nexium has already been approved for adults with GERD. Report [1]

> The FDA has given Novartis approval to market two higher doses of Diovan for high blood pressure. Report [2]

> Coley Pharmaceutical is touting the data from a Phase Ib for Actilon in patients with hep C. Report [3]

> Idenix says that a lower dose of valopicitabine with pegylated interferon demonstrated improved tolerability and comparable results in patients with hep C. Report [4]

> The large CRO Covance has expanded its operations in Singapore and China. Release [5]

> Canada's CV Technologies saw its stock jump on the news that the FDA would permit its cold remedy to be sold in the U.S. Report [6]

> J&J and Germany's Grunenthal plan to launch a late-stage trial of the experimental pain drug tapentadol. Report [7]

And Finally… After watching sales of Celebrex drop by half--to $1.7 billion--last year after imposing an ad moratorium, Pfizer is back marketing the drug. The move, complete with a highlighted warning on serious side effects, has renewed the argument over consumer ad campaigns. Article [8]